New combo aims to shrink liver tumors before surgery
NCT ID NCT07154082
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether giving a combination of targeted therapy (apatinib), immunotherapy (camrelizumab), and a procedure called TACE before surgery can help shrink centrally located liver tumors in people with stage B liver cancer. The goal is to make surgery more effective, reduce the risk of the cancer returning, and improve survival. The study plans to enroll 27 adults who have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apatinib mesylate (a targeted therapy) and camrelizumab (an immunotherapy) combined with transarterial chemoembolization (TACE)
- What this could lead to
- If successful, this approach could shrink liver tumors before surgery, making them easier to remove completely and potentially lowering the chance of cancer coming back.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination of drugs and TACE can cause side effects like fatigue, high blood pressure, or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?